XML 17 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenues:        
Clinical treatment programs - US $ 26 $ 35 $ 67 $ 125
Total Revenues 26 35 67 125
Costs and Expenses:        
Production costs 68 8 88 24
Research and development 607 1,437 2,861 4,533
General and administrative 1,798 3,079 5,830 9,485
Total Costs and Expenses 2,473 4,524 8,779 14,042
Operating loss (2,447) (4,489) (8,712) (13,917)
Gain (loss) on investments (1) 273 17 96
Interest and other income 3,052 718 3,073 3,379
Interest expense and other finance costs (148) (202) (421) (453)
Issuance Cost (433) (433)
Loss on issuance of warrants (3,977) (3,977) (458)
Change in fair value of warrants 670 670
Net Loss $ (3,284) $ (3,700) $ (9,783) $ (11,353)
Basic loss per share $ 1.57 $ (6.00) $ (8.18) $ (21.00)
Diluted loss per share $ 1.57 $ (6.00) $ (8.18) $ (21.00)
Weighted average shares outstanding basic 2,093,446 576,770 1,195,439 533,514
Weighted average shares outstanding diluted 2,093,446 576,770 1,195,439 533,514